Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1533 Articles

Chris Lange | Jun 12, 2019 at 8:30 AM EDT

Big Pharma Sees a Rising Tide in Short Interest

The May 31 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Jun 12, 2019 at 7:15 AM EDT

The 6 Most Shorted Dow Stocks

As of the most recently reported period, short sellers favored Pfizer, Intel and Apple above all other Dow stocks.

Chris Lange | May 28, 2019 at 8:50 AM EDT

Big Pharma Short Sellers Hike Their Bets

The May 15 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | May 28, 2019 at 7:10 AM EDT

Pfizer Overtakes Apple as Most Shorted Dow Stock

As of the most recently reported period, short sellers favored Pfizer, Intel and Apple above all other Dow stocks.

Lee Jackson | May 17, 2019 at 7:05 AM EDT

Merrill Lynch Has 5 Income Portfolio Stocks to Buy With Big-Time Dividends

24/7 Wall St. screened the Merrill Lynch Income Portfolio portfolio looking for high-yielding Buy-rated companies and found the following five…

Chris Lange | May 10, 2019 at 10:15 AM EDT

Big Pharma Scares Off Short Sellers

The April 30 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | May 10, 2019 at 7:50 AM EDT

Apple Overtakes Pfizer as Most Shorted Dow Stock

As of the most recently reported period, short sellers favored Apple, Intel and Pfizer above all other Dow stocks.

Jon C. Ogg | May 9, 2019 at 2:10 PM EDT

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and…

Paul Ausick | Apr 30, 2019 at 12:15 PM EDT

Why Pfizer Shareholders Are Smiling After Earnings

Drugmaker Pfizer beat estimates on both the top and bottom lines for the first quarter, and shares rallied after the…

Chris Lange | Apr 28, 2019 at 10:20 AM EDT

Apple, McDonald’s, Pfizer and More Dow Stocks Reporting This Week

24/7 Wall St. has put together a preview of Apple, Pfizer and other Dow companies scheduled to report their quarterly…

Chris Lange | Apr 26, 2019 at 8:45 AM EDT

Big Pharma Scares Off Short Sellers

The April 15 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Apr 26, 2019 at 6:45 AM EDT

6 Most Shorted Dow Stocks

As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.

Jon C. Ogg | Apr 24, 2019 at 7:10 AM EDT

15 Great Dividend Stocks Retirees Should Own in 2019

Here is a slate of 15 companies that most retirees likely would want to own in their portfolio now, including…

Chris Lange | Apr 10, 2019 at 9:40 AM EDT

Unbelievable Swings in Big Pharma Short Interest

The March 29 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Apr 10, 2019 at 7:30 AM EDT

The 5 Most Shorted Dow Stocks

As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.

1 … 31 32 33 34 35 … 103

Pfizer : PFE

All Pfizer Articles

Big Pharma Sees a Rising Tide in Short Interest

The 6 Most Shorted Dow Stocks

Big Pharma Short Sellers Hike Their Bets

Pfizer Overtakes Apple as Most Shorted Dow Stock

Merrill Lynch Has 5 Income Portfolio Stocks to Buy With Big-Time Dividends

Big Pharma Scares Off Short Sellers

Apple Overtakes Pfizer as Most Shorted Dow Stock

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

Why Pfizer Shareholders Are Smiling After Earnings

Apple, McDonald’s, Pfizer and More Dow Stocks Reporting This Week

Big Pharma Scares Off Short Sellers

6 Most Shorted Dow Stocks

15 Great Dividend Stocks Retirees Should Own in 2019

Unbelievable Swings in Big Pharma Short Interest

The 5 Most Shorted Dow Stocks

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Pfizer : PFE

All Pfizer Articles

Big Pharma Sees a Rising Tide in Short Interest

The 6 Most Shorted Dow Stocks

Big Pharma Short Sellers Hike Their Bets

Pfizer Overtakes Apple as Most Shorted Dow Stock

Merrill Lynch Has 5 Income Portfolio Stocks to Buy With Big-Time Dividends

Big Pharma Scares Off Short Sellers

Apple Overtakes Pfizer as Most Shorted Dow Stock

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

Why Pfizer Shareholders Are Smiling After Earnings

Apple, McDonald’s, Pfizer and More Dow Stocks Reporting This Week

Big Pharma Scares Off Short Sellers

6 Most Shorted Dow Stocks

15 Great Dividend Stocks Retirees Should Own in 2019

Unbelievable Swings in Big Pharma Short Interest

The 5 Most Shorted Dow Stocks

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Featured Reads

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.